Sign in or create an account to add this stock to your watchlist.
About Dova Pharmaceuticals (NASDAQ:DOVA)
Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease. Dova Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Durham, North Carolina.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DOVA
CUSIPN/A
Phone919-748-5975
Debt
Debt-to-Equity RatioN/A
Current Ratio35.32
Quick Ratio35.32
Price-To-Earnings
Trailing P/E Ratio-17.26
Forward P/E Ratio-11.24
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.38 per share
Price / Book10.15
Profitability
EPS (Most Recent Fiscal Year)($1.40)
Net Income$-29,950,000.00
Net MarginsN/A
Return on Equity-61.19%
Return on Assets-43.40%
Miscellaneous
Employees33
Outstanding Shares28,190,000
Dova Pharmaceuticals (NASDAQ:DOVA) Frequently Asked Questions
What is Dova Pharmaceuticals' stock symbol?
Dova Pharmaceuticals trades on the NASDAQ under the ticker symbol "DOVA."
How were Dova Pharmaceuticals' earnings last quarter?
Dova Pharmaceuticals (NASDAQ:DOVA) announced its earnings results on Wednesday, May, 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.47) by $0.05. View Dova Pharmaceuticals' Earnings History.
What price target have analysts set for DOVA?
4 analysts have issued 12-month price targets for Dova Pharmaceuticals' shares. Their forecasts range from $29.00 to $35.00. On average, they expect Dova Pharmaceuticals' stock price to reach $32.25 in the next year. View Analyst Ratings for Dova Pharmaceuticals.
Who are some of Dova Pharmaceuticals' key competitors?
Some companies that are related to Dova Pharmaceuticals include Supernus Pharmaceuticals (SUPN), Ascendis Pharma (ASND), Ironwood Pharmaceuticals (IRWD), Portola Pharmaceuticals (PTLA), Clovis Oncology (CLVS), Tesaro (TSRO), Emergent BioSolutions (EBS), Horizon Pharma (HZNP), Global Blood Therapeutics (GBT), The Medicines (MDCO), Heron Therapeutics (HRTX), ACADIA Pharmaceuticals (ACAD), Arena Pharmaceuticals (ARNA), OPKO Health (OPK) and Evotec A.G. (EVTCY).
Who are Dova Pharmaceuticals' key executives?
Dova Pharmaceuticals' management team includes the folowing people:
- Mr. Alexander C. Sapir, Pres, CEO & Director (Age 51)
- Dr. Lee F. Allen, Chief Medical Officer (Age 66)
- Mr. Mark W. Hahn, Chief Financial Officer (Age 55)
- Mr. Kevin Laliberte, Sr. VP of Product Devel. (Age 40)
When did Dova Pharmaceuticals IPO?
(DOVA) raised $66 million in an initial public offering on Thursday, June 29th 2017. The company issued 4,100,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Leerink Partners acted as the underwriters for the IPO.
Has Dova Pharmaceuticals been receiving favorable news coverage?
News articles about DOVA stock have been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Dova Pharmaceuticals earned a media sentiment score of 0.13 on Accern's scale. They also assigned news headlines about the company an impact score of 46.41 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are Dova Pharmaceuticals' major shareholders?
Dova Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.30%), Nexthera Capital LP (2.02%), Wells Fargo & Company MN (1.20%), Pier Capital LLC (0.77%), GW&K Investment Management LLC (0.51%) and venBio Select Advisor LLC (0.44%). Company insiders that own Dova Pharmaceuticals stock include Alex Sapir, Kevin Laliberte, Lee F Md Phd Allen, Paul B Manning and Steven M Goldman. View Institutional Ownership Trends for Dova Pharmaceuticals.
Which major investors are buying Dova Pharmaceuticals stock?
DOVA stock was purchased by a variety of institutional investors in the last quarter, including GW&K Investment Management LLC, venBio Select Advisor LLC, Nexthera Capital LP, Candriam Luxembourg S.C.A., BlackRock Inc., Citigroup Inc., Pier Capital LLC and Wells Fargo & Company MN. Company insiders that have bought Dova Pharmaceuticals stock in the last two years include Alex Sapir, Kevin Laliberte, Lee F Md Phd Allen, Paul B Manning and Steven M Goldman. View Insider Buying and Selling for Dova Pharmaceuticals.
How do I buy shares of Dova Pharmaceuticals?
Shares of DOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dova Pharmaceuticals' stock price today?
One share of DOVA stock can currently be purchased for approximately $24.1650.
How big of a company is Dova Pharmaceuticals?
Dova Pharmaceuticals has a market capitalization of $784.84 million. The company earns $-29,950,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. Dova Pharmaceuticals employs 33 workers across the globe.
How can I contact Dova Pharmaceuticals?
Dova Pharmaceuticals' mailing address is 240 Leigh Farm Road Suite 245, Durham NC, 27707. The company can be reached via phone at 919-748-5975 or via email at [email protected]
MarketBeat Community Rating for Dova Pharmaceuticals (DOVA)
MarketBeat's community ratings are surveys of what our community members think about Dova Pharmaceuticals and other stocks. Vote "Outperform" if you believe DOVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DOVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Dova Pharmaceuticals (NASDAQ:DOVA) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Dova Pharmaceuticals in the last 12 months. Their average twelve-month price target is $32.25, suggesting that the stock has a possible upside of 33.46%. The high price target for DOVA is $35.00 and the low price target for DOVA is $29.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $32.25 | $32.25 | $33.3333 | $32.3333 |
| Price Target Upside: | 33.46% upside | 7.57% upside | 16.43% upside | 44.02% upside |
Dova Pharmaceuticals (NASDAQ:DOVA) Consensus Price Target History
Dova Pharmaceuticals (NASDAQ:DOVA) Analyst Ratings History
Show:
(Data available from 5/22/2016 forward)
Dova Pharmaceuticals (NASDAQ:DOVA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Dova Pharmaceuticals (NASDAQ DOVA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 55.50%
Institutional Ownership Percentage: 35.93%
Dova Pharmaceuticals (NASDAQ DOVA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/16/2017 | Paul B Manning | Director | Buy | 25,870 | $22.30 | $576,901.00 | |  |
| 8/15/2017 | Steven M Goldman | Director | Buy | 20,169 | $22.23 | $448,356.87 | 81,158 | |
| 7/5/2017 | Alex Sapir | CEO | Buy | 20,100 | $17.00 | $341,700.00 | 20,100 | |
| 7/5/2017 | Kevin Laliberte | VP | Buy | 6,200 | $17.00 | $105,400.00 | 6,200 | |
| 7/5/2017 | Lee F Md Phd Allen | Insider | Buy | 3,500 | $17.00 | $59,500.00 | 3,500 | |
| 7/5/2017 | Steven M Goldman | Director | Buy | 72,000 | $17.94 | $1,291,680.00 | 42,000 | |
(Data available from 1/1/2013 forward)
Dova Pharmaceuticals (NASDAQ DOVA) News Headlines
| Source: |
|
Dova Pharmaceuticals (NASDAQ:DOVA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Dova Pharmaceuticals (NASDAQ:DOVA) Income Statement, Balance Sheet and Cash Flow Statement
Dova Pharmaceuticals (NASDAQ DOVA) Stock Chart for Tuesday, May, 22, 2018
Loading chart…
